Form 4: Theravance Biopharma Director Reports Acquisition and Disposal of Shares

Director Deepika Pakianathan reports acquisition of shares and disposal of shares in Theravance Biopharma, Inc.

Summary

• On May 8, 2024, Deepika Pakianathan, a director of Theravance Biopharma, Inc., reported changes in beneficial ownership of the company's securities.
• Pakianathan acquired 10,537 ordinary shares at $0.
• Pakianathan disposed of 47,416 ordinary shares.
• Following the transaction, Pakianathan beneficially owns 23,576 ordinary shares.
• Pakianathan also acquired 23,576 share options with an exercise price of $9.49, exercisable from May 8, 2024, until May 7, 2034.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with both acquisition and disposal of shares. The sentiment is neutral as it's a routine disclosure.

Positives

• The acquisition of share options by a director could be seen as a positive sign of confidence in the company's future.

Negatives

• The disposal of 47,416 ordinary shares by a director could be interpreted negatively by investors.

Risks

• The vesting schedule of the share options is contingent on continuous service, which introduces a risk of forfeiture if the director leaves the company.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders. It provides transparency into the trading activities of company directors and officers, which can be informative for investors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The vesting schedule of the options is fairly standard, with monthly vesting and a final vesting date at the next annual meeting.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates